Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa
Journal
Antimicrobial Agents and Chemotherapy
ISSN
0066-4804
1098-6596
Date Issued
2022
Author(s)
Manuel Alcalde-Rico
José R. W. Martínez
María Victoria Moreno
Pamela Rojas
Aniela Wozniak
Patricia García
Jorge Olivares-Pacheco
William R. Miller
Cesar A. Arias
Ayesha Khan
Type
Resource Types::text::journal::journal article
URL Institutional Repository
Abstract
<jats:p>
Ceftolozane/tazbactam (C/T) is a potent anti-pseudomonal agent that has clinical utility against infections caused by non-carbapenemase, producing-carbapenem-resistant
<jats:named-content content-type="genus-species">Pseudomonas aeruginosa</jats:named-content>
(non-CP-CR-PA). Accurate, precise, and reliable antimicrobial susceptibility testing (AST) is crucial to guide clinical decisions.
</jats:p>
Ceftolozane/tazbactam (C/T) is a potent anti-pseudomonal agent that has clinical utility against infections caused by non-carbapenemase, producing-carbapenem-resistant
<jats:named-content content-type="genus-species">Pseudomonas aeruginosa</jats:named-content>
(non-CP-CR-PA). Accurate, precise, and reliable antimicrobial susceptibility testing (AST) is crucial to guide clinical decisions.
</jats:p>
Cite this document
Rivas, L., Alcalde-Rico, M., Martínez, J. R. W., Moreno, M. V., Rojas, P., Wozniak, A., García, P., Olivares-Pacheco, J., Miller, W. R., Arias, C. A., Khan, A., & Munita, J. M. (2022). Real-world performance of susceptibility testing for ceftolozane/tazobactam against non-carbapenemase-producing carbapenem-resistant pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 66(1), e01657-21. https://doi.org/10.1128/AAC.01657-21
Subjects
ceftolozane/tazobactam
;
susceptibility testing
;
pseudomonas aeruginosa
;
non-carbapenemase-producing
;
carbapenem-resistant p. aeruginosa
;
gram-negative bacteria
;
pseudomonas
;
antibiotic resistance
;
antimicrobial activity
;
beta-lactams
;
bloodstream infections
;
infectious disease
;
multidrug resistance
;
anti-bacterial agents
;
carbapenems
;
cephalosporins
;
humans
;
microbial sensitivity tests
;
pseudomonas aeruginosa
;
pseudomonas infections
;
tazobactam
;
amikacin
;
aztreonam
;
beta lactam
;
carbapenemase
;
cefepime
;
ceftazidime
;
ceftolozane plus tazobactam
;
ciprofloxacin
;
gentamicin
;
imipenem
;
meropenem
;
piperacillin plus tazobactam
;
antiinfective agent
;
carbapenem derivative
;
ceftolozane
;
cephalosporin derivative
;
tazobactam
;
antibiotic sensitivity
;
antimicrobial activity
;
article
;
broth dilution
;
carbapenem resistant pseudomonas aeruginosa
;
disk diffusion
;
matrix assisted laser desorption ionization time of flight mass spectrometry
;
mic50
;
mic90
;
minimum inhibitory concentration
;
multiplex polymerase chain reaction
;
nonhuman
;
human
;
microbial sensitivity test
;
pseudomonas aeruginosa
;
pseudomonas infection